vs
安进（AMGN）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Pediatrix Medical Group, Inc.的20.0倍（$9.9B vs $493.8M）。安进净利率更高（13.5% vs 6.8%，领先6.7%）。安进同比增速更快（8.6% vs -1.7%）。过去两年安进的营收复合增速更高（15.1% vs -0.1%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
AMGN vs MD — 直观对比
营收规模更大
AMGN
是对方的20.0倍
$493.8M
营收增速更快
AMGN
高出10.3%
-1.7%
净利率更高
AMGN
高出6.7%
6.8%
两年增速更快
AMGN
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $493.8M |
| 净利润 | $1.3B | $33.7M |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | 9.9% |
| 净利率 | 13.5% | 6.8% |
| 营收同比 | 8.6% | -1.7% |
| 净利润同比 | 112.6% | 10.5% |
| 每股收益（稀释后） | $2.45 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNMD
| Q4 25 | $9.9B | $493.8M | ||
| Q3 25 | $9.6B | $492.9M | ||
| Q2 25 | $9.2B | $468.8M | ||
| Q1 25 | $8.1B | $458.4M | ||
| Q4 24 | $9.1B | $502.4M | ||
| Q3 24 | $8.5B | $511.2M | ||
| Q2 24 | $8.4B | $504.3M | ||
| Q1 24 | $7.4B | $495.1M |
净利润AMGNMD
| Q4 25 | $1.3B | $33.7M | ||
| Q3 25 | $3.2B | $71.7M | ||
| Q2 25 | $1.4B | $39.3M | ||
| Q1 25 | $1.7B | $20.7M | ||
| Q4 24 | $627.0M | $30.5M | ||
| Q3 24 | $2.8B | $19.4M | ||
| Q2 24 | $746.0M | $-153.0M | ||
| Q1 24 | $-113.0M | $4.0M |
毛利率AMGNMD
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNMD
| Q4 25 | 27.6% | 9.9% | ||
| Q3 25 | 26.4% | 13.8% | ||
| Q2 25 | 28.9% | 12.8% | ||
| Q1 25 | 14.5% | 7.0% | ||
| Q4 24 | 25.4% | 7.8% | ||
| Q3 24 | 24.1% | 6.6% | ||
| Q2 24 | 22.8% | -31.3% | ||
| Q1 24 | 13.3% | 3.2% |
净利率AMGNMD
| Q4 25 | 13.5% | 6.8% | ||
| Q3 25 | 33.7% | 14.5% | ||
| Q2 25 | 15.6% | 8.4% | ||
| Q1 25 | 21.2% | 4.5% | ||
| Q4 24 | 6.9% | 6.1% | ||
| Q3 24 | 33.3% | 3.8% | ||
| Q2 24 | 8.9% | -30.3% | ||
| Q1 24 | -1.5% | 0.8% |
每股收益（稀释后）AMGNMD
| Q4 25 | $2.45 | $0.40 | ||
| Q3 25 | $5.93 | $0.84 | ||
| Q2 25 | $2.65 | $0.46 | ||
| Q1 25 | $3.20 | $0.24 | ||
| Q4 24 | $1.17 | $0.37 | ||
| Q3 24 | $5.22 | $0.23 | ||
| Q2 24 | $1.38 | $-1.84 | ||
| Q1 24 | $-0.21 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $375.2M |
| 总债务越低越好 | $54.6B | $570.5M |
| 股东权益账面价值 | $8.7B | $865.9M |
| 总资产 | $90.6B | $2.2B |
| 负债/权益比越低杠杆越低 | 6.31× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资AMGNMD
| Q4 25 | $9.1B | $375.2M | ||
| Q3 25 | $9.4B | $340.1M | ||
| Q2 25 | $8.0B | $224.7M | ||
| Q1 25 | $8.8B | $99.0M | ||
| Q4 24 | $12.0B | $229.9M | ||
| Q3 24 | $9.0B | $103.8M | ||
| Q2 24 | $9.3B | $19.4M | ||
| Q1 24 | $9.7B | $8.0M |
总债务AMGNMD
| Q4 25 | $54.6B | $570.5M | ||
| Q3 25 | $54.6B | $577.2M | ||
| Q2 25 | $56.2B | $583.9M | ||
| Q1 25 | $57.4B | $590.5M | ||
| Q4 24 | $60.1B | $597.1M | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNMD
| Q4 25 | $8.7B | $865.9M | ||
| Q3 25 | $9.6B | $890.7M | ||
| Q2 25 | $7.4B | $833.8M | ||
| Q1 25 | $6.2B | $789.2M | ||
| Q4 24 | $5.9B | $764.9M | ||
| Q3 24 | $7.5B | $732.5M | ||
| Q2 24 | $5.9B | $706.5M | ||
| Q1 24 | $5.0B | $856.2M |
总资产AMGNMD
| Q4 25 | $90.6B | $2.2B | ||
| Q3 25 | $90.1B | $2.2B | ||
| Q2 25 | $87.9B | $2.1B | ||
| Q1 25 | $89.4B | $2.0B | ||
| Q4 24 | $91.8B | $2.2B | ||
| Q3 24 | $90.9B | $2.1B | ||
| Q2 24 | $90.9B | $2.0B | ||
| Q1 24 | $93.0B | $2.2B |
负债/权益比AMGNMD
| Q4 25 | 6.31× | 0.66× | ||
| Q3 25 | 5.67× | 0.65× | ||
| Q2 25 | 7.57× | 0.70× | ||
| Q1 25 | 9.24× | 0.75× | ||
| Q4 24 | 10.23× | 0.78× | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 6.5% | — |
| 现金转化率经营现金流/净利润 | 1.20× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $8.1B | — |
8季度趋势，按日历期对齐
经营现金流AMGNMD
| Q4 25 | $1.6B | $114.1M | ||
| Q3 25 | $4.7B | $137.3M | ||
| Q2 25 | $2.3B | $137.2M | ||
| Q1 25 | $1.4B | $-117.5M | ||
| Q4 24 | $4.8B | $133.0M | ||
| Q3 24 | $3.6B | $91.8M | ||
| Q2 24 | $2.5B | $107.0M | ||
| Q1 24 | $689.0M | $-125.2M |
自由现金流AMGNMD
| Q4 25 | $961.0M | — | ||
| Q3 25 | $4.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $980.0M | — | ||
| Q4 24 | $4.4B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $459.0M | — |
自由现金流率AMGNMD
| Q4 25 | 9.7% | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 48.4% | — | ||
| Q3 24 | 39.0% | — | ||
| Q2 24 | 26.5% | — | ||
| Q1 24 | 6.2% | — |
资本支出强度AMGNMD
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.1% | — |
现金转化率AMGNMD
| Q4 25 | 1.20× | 3.39× | ||
| Q3 25 | 1.46× | 1.91× | ||
| Q2 25 | 1.59× | 3.49× | ||
| Q1 25 | 0.80× | -5.66× | ||
| Q4 24 | 7.61× | 4.36× | ||
| Q3 24 | 1.26× | 4.72× | ||
| Q2 24 | 3.30× | — | ||
| Q1 24 | — | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
